sublingual

舌下
  • 文章类型: Journal Article
    RSV感染仍然是全世界儿童的严重威胁,尤其是,在中低收入国家。经由粘膜的疫苗递送具有在呼吸道中诱导局部免疫应答的巨大潜力。以前,我们报道了高免疫原性RSV病毒样颗粒(RSV-VLP)的发展,其基础是构象稳定的前-F蛋白(preFg),糖蛋白和基质蛋白。这里,探讨RSV-VLPs的粘膜递送是否是诱导RSV特异性粘膜和全身免疫的有效策略,RSV-VLP经鼻给药,BALB/c小鼠的舌下和肺部途径。结果表明,通过粘膜途径用VLP免疫诱导最小的粘膜反应,但促进适度水平的血清IgG抗体,增强的T细胞反应和脾细胞上肺归巢标志物CXCR3的表达。通过所有三种粘膜途径用VLP免疫提供针对RSV攻击的保护,而没有RSV诱导的病理学的迹象。
    RSV infection remains a serious threat to the children all over the world, especially, in the low-middle income countries. Vaccine delivery via the mucosa holds great potential for inducing local immune responses in the respiratory tract. Previously, we reported the development of highly immunogenic RSV virus-like-particles (RSV-VLPs) based on the conformationally stable prefusogenic-F protein (preFg), glycoprotein and matrix protein. Here, to explore whether mucosal delivery of RSV-VLPs is an effective strategy to induce RSV-specific mucosal and systemic immunity, RSV-VLPs were administered via the nasal, sublingual and pulmonary routes to BALB/c mice. The results demonstrate that immunization with the VLPs via the mucosal routes induced minimal mucosal response and yet facilitated modest levels of serum IgG antibodies, enhanced T cell responses and the expression of the lung-homing marker CXCR3 on splenocytes. Immunization with VLPs via all three mucosal routes provided protection against RSV challenge with no signs of RSV induced pathology.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Case Reports
    (1)背景:舌下间隙皮样囊肿并不常见,通常表现为无痛,群众逐渐扩大,通常直径不超过3厘米。由于其临床表现,这些囊肿可能类似于各种疾病,在口腔中的发生率相对较低,约占所有皮样囊肿的1.6%。(2)方法:我们介绍了一例17岁的女性,患有累及下颌的巨大皮样囊肿,舌下,和语言区域,几年来未确诊。通过MRI和细针穿刺获得诊断,导致通过子宫颈入路手术切除的决定。(3)结果:愈合过程顺利。手术后的第一天,病人开始了肌功能疗法,成功地恢复了适当的舌头功能。在24个月的随访中,患者保持无症状。(4)结论:宫颈入路可成功治疗累及颌下的巨大口腔皮样囊肿,舌下,和语言空间。手术治疗后,通过肌功能疗法可以成功恢复舌功能。
    (1) Background: Dermoid cysts occurring in the sublingual space are uncommon, typically manifesting as painless, gradually enlarging masses, usually not exceeding 3 cm in diameter. These cysts can resemble various conditions due to their clinical presentation, with a relatively low occurrence rate in the oral cavity, accounting for about 1.6% of all dermoid cysts. (2) Methods: We present the case of a 17-year-old female with a giant dermoid cyst involving the submental, sublingual, and lingual areas, undiagnosed for several years. Diagnosis was achieved through MRI and fine-needle aspiration, leading to the decision for surgical removal through a cervical approach. (3) Results: The healing process was uneventful. From the first day post-surgery, the patient began myofunctional therapy, successfully regaining proper tongue functions. Throughout a 24-month follow-up, the patient remained symptom-free. (4) Conclusions: A cervical approach can successfully treat giant oral dermoid cysts involving submental, sublingual, and lingual spaces. Tongue function can be successfully regained through myofunctional therapy after surgical treatment.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    神经鞘瘤生长缓慢,由雪旺氏细胞引起的良性肿瘤。它们通常是孤立的,有时与1型和2型神经纤维瘤病有关。据Okada等人报道。,虽然大约25%-40%的颅外神经鞘瘤发生在头颈部,口腔神经鞘瘤非常罕见,仅占所有神经鞘瘤的1%。我们报告了一例47岁女性舌下神经鞘瘤,在耳鸣检查中偶然发现的。放射学和组织病理学发现,连同文献综述,被呈现。
    Schwannomas are slow growing, benign tumours arising from Schwann cells. They are usually solitary and are sometimes associated with Neurofibromatosis type 1 and 2. As reported by Okada et al., while approximately 25%-40% of extra-cranial schwannomas occur in the head and neck region, Schwannomas of the oral cavity are very uncommon, accounting for only 1% of all Schwannomas. We report a case of a sublingual schwannoma in a 47-year-old female, discovered incidentally during the workup for tinnitus. The radiological and histopathological findings, along with a literature review, are presented.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    一名89岁的非尼托硫磷毒性患者接受了舌下阿托品滴眼液,减少静脉阿托品的需求。这种替代方法可以快速康复,他独自行走,导致放电。
    An 89-year-old patient with fenitrothion toxicity received sublingual atropine eye drops, reducing the intravenous atropine requirement. This alternative method enabled rapid rehabilitation, and he walked unaided, leading to discharge.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:在过去的几年里,医用大麻产品的使用急剧增加,以扩大临床适应症的范围。药物产品的类型及其给药途径基本上影响大麻素的吸收速率和程度以及它们在患者中诱导的作用。大麻制药工业当前的挑战是开发允许大麻素的可预测和稳定吸收的制剂。本文报告了研究健康志愿者中创新大麻产品的药代动力学(PKs)的临床试验结果。材料和方法:这是一项单剂量单中心研究,随机化,交叉,部分盲控制设计。12名健康志愿者每人接受了8种不同的产品,在这项试验中评估的10种产品中:新型舌下(SL)片剂,蒸发器,和直肠产品,比较产品(Sativex®和油基口腔粘膜产品),和安慰剂产品。收集了连续的血液样本,THC的血浆浓度,11-OH-THC,和CBD进行了定量和非房室PK分析。结果:研究中调查的新型医用大麻产品诱导志愿者大量接触活性成分,吸收更快,在某些情况下,THC和CBD的可变吸收也较少,与批准的比较产品相比。新型SL片剂和栓剂产品的生物利用度略低于口腔粘膜产品。蒸发器提供具有最高最大浓度的即时全身吸收。新型大麻产品的安全性,即蒸发器,SL片,和栓剂,不逊于Sativex和油基口腔粘膜制剂。结论:本研究中评估的新型大麻产品具有PK特性,可能有利于特定医疗条件的管理或处方医用大麻的患者的特定亚组。
    Background: Over the last years, there is a dramatic increase in the use of medical cannabis products for an expanding range of clinical indications. The type of the drug product and its administration route affect substantially the rate and the extent of absorption of cannabinoids and the effects induced by them in the patients. The current challenge for the cannabis pharmaceutical industry is to develop formulations that allow predictable and stable absorption of cannabinoids. This article reports the results of the clinical trial that investigated the pharmacokinetics (PKs) of innovative cannabis products in healthy volunteers. Materials and Methods: This was a single-center study with a single-dose, randomized, crossover, partially blinded controlled design. Each of the 12 healthy volunteers received 8 different products, of the 10 products that were assessed in this trial: novel sublingual (SL) tablet, vaporizer, and rectal products, comparator products (Sativex® and oil-based oromucosal products), and placebo products. Serial blood samples were collected, plasma concentrations of the THC, 11-OH-THC, and CBD were quantified and subjected to noncompartmental PK analysis. Results: Novel medical cannabis products that were investigated in the study induced substantial exposure of the volunteers to the active ingredients, had more rapid absorption, and in some cases also less variable absorption of THC and CBD, in comparison with the approved comparison products. The bioavailability of the novel SL tablet-based and suppositories products was somewhat lower than that of the oromucosal products. The vaporizer provided immediate systemic absorption with highest maximal concentration. The safety profile of the novel cannabis products, namely vaporizer, SL tablets, and suppositories, was not inferior to the Sativex and oil-based oromucosal formulations. Conclusions: The novel cannabis products that were assessed in this study have PK properties that may be advantageous for management of specific medical conditions or in specific subgroups of patients that are prescribed medical cannabis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Review
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:本系统综述和网络荟萃分析旨在评估维生素B12的三种不同给药途径:口服,肌内(IM),和舌下(SL)路由。
    方法:我们搜索了四个电子数据库(PubMed,Scopus,WebofScience,和科克伦中央对照试验登记册)。我们只包括比较研究。我们进行了频繁的网络荟萃分析来衡量相对结果的网络估计。此外,我们使用随机效应模型进行了成对meta分析,以获得结局的直接估计值.所有结果都是连续的,将相对治疗效果合并为平均差(MD)和95%置信区间.
    结果:13项研究纳入荟萃分析,共有4275名患者。关于增加维生素B12水平,IM路线排名第一,其次是SL路线(MD=94.09和43.31pg/mL,分别)与口服途径相比。然而,由于研究数量有限,这些差异未达到统计学意义.关于血红蛋白水平,合并效应大小显示,所有给药途径之间均无统计学差异.然而,排名前两位的给药途径是口服途径(78.3)和IM途径(49.6).
    结论:所有IM,口服,和SL途径的维生素B12给药可以有效提高维生素B12的水平,它们之间没有显着差异,正如之前所想的。然而,IM途径在统计学上排名最高,但无临床意义.我们发现在所有其他CBC参数和高半胱氨酸水平的研究给药途径之间没有显着差异。
    BACKGROUND: This systematic review and network meta-analysis aimed to evaluate the three different administration routes of vitamin B12: oral, intramuscular (IM), and sublingual (SL) routes.
    METHODS: We searched four electronic databases (PubMed, Scopus, Web of Science, and Cochrane CENTRAL Register of Controlled Trials). We included only comparative studies. We performed a frequentist network meta-analysis to measure network estimates for the relative outcomes. Moreover, we conducted a pairwise meta-analysis using a random effect model to obtain direct estimates for outcomes. All outcomes were continuous, and the relative treatment effects were pooled as mean difference (MD) with 95% confidence intervals.
    RESULTS: Thirteen studies were included in the meta-analysis, with a total of 4275 patients. Regarding increasing vitamin B12 levels, the IM route ranked first, followed by the SL route (MD = 94.09 and 43.31 pg/mL, respectively) compared to the oral route. However, these differences did not reach statistical significance owing to the limited number of studies. Regarding the hemoglobin level, the pooled effect sizes showed no difference between all routes of administration that could reach statistical significance. However, the top two ranked administration routes were the oral route (78.3) and the IM route (49.6).
    CONCLUSIONS: All IM, oral, and SL routes of administration of vitamin B12 can effectively increase the level of vitamin B12 without significant differences between them, as thought previously. However, the IM route was the top-ranked statistically but without clinical significance. We found no significant difference among studied administrated routes in all other CBC parameters and homocysteine levels.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    微循环对于细胞生命及其功能至关重要。它包括一个复杂的毛细血管网络,小动脉,和小静脉,根据区域代谢需求在器官中和器官内分配含氧血液。因为先前的研究表明器官功能与微循环功能有关,在大手术期间维持足够和有效的微循环功能至关重要。微循环受损会导致组织灌注不足,可能导致围手术期并发症和不利的结果。的确,心血管疾病和心脏手术中微循环的变化与术后重症监护病房的住院时间延长和30天内的高死亡率直接相关.此外,体外循环,心脏手术中经常使用的方法,已经被证明会引起微循环故障,因此,导致术后多器官功能障碍。由于全局血液动力学参数可以保持稳定或改善,虽然微循环仍然受到损害,跟踪微循环变量可导致在血流动力学管理中发展靶向微循环治疗.因此,有必要加强微循环监测在医学领域的使用,以协助医生对接受心脏手术的患者进行治疗管理。这可能导致更好的血液动力学管理和结果。这篇综述文章集中于手持视频显微镜在术后即刻和早期对心脏手术患者进行实时微循环评估。在接受心脏手术的患者的治疗管理中,重点放在将微循环监测与常规血液动力学监测相结合。
    Microcirculation is essential for cellular life and its functions. It comprises a complex network of capillaries, arterioles, and venules, which distributes oxygenated blood across and within organs based on regional metabolic demands. Because previous research indicated that organ function is linked to microcirculatory function, it is crucial to maintain sufficient and effective microcirculatory function during major surgery. Impaired microcirculation can lead to inadequate tissue perfusion, potentially resulting in perioperative complications and an unfavorable outcome. Indeed, changes in microcirculation in cardiovascular disease and cardiac surgery have a direct correlation with prolonged stays in the postoperative intensive care unit and high mortality rates within 30 days. Additionally, cardiopulmonary bypass, a regularly employed method in cardiac surgery, has been proven to induce microcirculatory malfunction and, thus, lead to postoperative multiple organ dysfunction. As global hemodynamic parameters can remain stable or improve, whereas microcirculation is still compromised, tracking microcirculatory variables could lead to the development of targeted microcirculatory treatment within hemodynamic management. Therefore, it is necessary to enhance the use of microcirculatory monitoring in the medical domain to assist physicians in the therapeutic management of patients undergoing cardiac surgery. This potentially can lead to better hemodynamic management and outcomes. This review article concentrates on the use of handheld video microscopes for real-time microcirculatory assessment of cardiac surgery patients in the immediate and early postoperative period. Emphasis is placed on integrating microcirculatory monitoring with conventional hemodynamic monitoring in the therapeutic management of patients undergoing cardiac surgery.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    过敏原免疫疗法(AIT)是过敏性疾病的唯一病因疗法,因此尤为重要。自1989年以来,过敏原制剂已被归类为医药产品(指令89/342/EEC),并于2001年被纳入指令2001/83/EC。此外,2008年,《治疗变应原条例》(TAO)生效,以更严格地规范指定患者产品(NPP)的例外,将普通治疗变应原排除在作为NPP销售的例外之外。TAO规范了这些常见治疗过敏原的安全性和有效性测试要求。由于长期的过渡性规定,解决临床缺陷的最后期限将在2026年结束。该法规的优点是,普通过敏原的市场已经清除了没有功效证明的产品,并通过剂量发现研究开发了具有最佳剂量范围的新制剂。EMA儿科委员会(PDCO)的过敏原产品标准儿科调查计划(PIP)概述了对长期儿科研究的需求。这尤其成问题,因为可以预见,患者的招募将受到限制,并且长期使用安慰剂会引起伦理问题。此外,在可预见的未来,许多新批准的制剂将不会用于儿科,因为这个年龄组还没有获得营销授权。这将导致儿童的严重供应缺口。
    Allergen immunotherapy (AIT) is the only causal therapy for allergic diseases and therefore particularly important. Allergen preparations have been classified as medicinal products since 1989 (Directive 89/342/EEC) and were taken over into Directive 2001/83/EC in 2001. In addition, in 2008 the Therapy Allergen Ordinance (TAO) came into force to stricter regulate the exception for named patient products (NPP) by exclusion of common therapy allergens from the exception to be marketed as NPP. The TAO regulates the requirements for testing safety and efficacy for these common therapy allergens. Due to the long transitional provisions, the last deadlines for solving clinical shortcomings will end in 2026. The advantage of this regulation is that the market for common allergens has been cleared of products without proof of efficacy, and new preparations with an optimal dose range are developed through dose-finding studies. The demand for long-term pediatric studies has been outlined by the standard Pediatric Investigation Plan (PIP) on allergen products from the Pediatric Committee of the EMA (PDCO). This is particularly problematic, as it is foreseeable that recruitment of patients will be limited and ethical problems arise from the prolonged use of placebo. Furthermore, many newly approved preparations will not be used in pediatrics for the foreseeable future, as no marketing authorization has yet been granted for this age group. This will result in a serious supply gap for children.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    消化内镜检查(DE)对大多数患者来说是不舒服的。劳拉西m是一种具有抗焦虑和镇静作用的强效苯二氮卓类药物。
    本研究旨在确定舌下劳拉西泮与安慰剂作为术前用药对接受DE的患者的镇静作用。
    这是一个单中心,双盲,和随机对照试验。
    研究人员制作了劳拉西泮舌下片,并对其进行了物理测试,然后进行了双盲安慰剂对照试验,以研究舌下给药2mg劳拉西泮作为内镜术前用药的疗效.在内窥镜检查前30分钟舌下给予劳拉西m或安慰剂片。病人,护士,医生对患者组视而不见。根据美国麻醉学会评估镇静的深度。
    总之,116名患者被随机分配服用劳拉西泮(n=58)或安慰剂(n=58)。根据美国药典,物理性质测试的结果是可接受的。组间年龄和性别无统计学差异。在劳拉西泮组中,75.8%的患者表现为轻度镇静,24.2%的患者无镇静。安慰剂组的所有患者均无镇静作用(p=0.001)。手术时间(p<0.001),术中O2饱和度(p<0.001),术中心率(p<0.001),劳拉西泮组和术中血压(p<0.001)显著降低。除了有点头晕和头晕外,没有观察到明显或危险的副作用。
    这项研究的结果表明,在内窥镜检查前25-30分钟服用舌下劳拉西泮可提供轻度镇静作用。
    IRCT201611039014N130(2016年5月11日);https://en。irct.ir/trial/9568。
    UNASSIGNED: Digestive endoscopy (DE) is uncomfortable for most patients. Lorazepam is a potent benzodiazepine with anxiolytic and sedative effects.
    UNASSIGNED: This study aims to determine the sedative effect of sublingual lorazepam versus placebo as a premedication in patients who underwent DE.
    UNASSIGNED: This is a mono-center, double-blind, and randomized controlled trial.
    UNASSIGNED: A lorazepam sublingual tablet was made by researchers and physical tests were done on it, then the double-blind placebo-controlled trial was done to investigate the efficacy of 2 mg sublingually administered lorazepam as a premedication for endoscopy. Lorazepam or a placebo tablet was administered sublingually 30 min before the endoscopy. The patients, nurses, and physicians were blinded to the patient group. The depth of sedation was evaluated according to the American Society of Anesthesiology.
    UNASSIGNED: In all, 116 patients were randomly assigned to take either lorazepam (n = 58) or a placebo (n = 58). The results of physical properties tests were acceptable according to United States Pharmacopeia. There were no statistical differences between groups regarding age and gender. In the lorazepam group, 75.8% of patients showed mild sedation, and 24.2% of patients showed no sedation. All of the patients in the placebo had no sedation (p = 0.001). Time of procedure (p < 0.001), intraoperative O2 saturation (p < 0.001), intraoperative heart rate (p < 0.001), and intraoperative blood pressure (p < 0.001) were significantly lower in the lorazepam group. No significant or dangerous side effects were observed except a bit of giddiness and dizziness.
    UNASSIGNED: The results of this study showed that prescription of sublingual lorazepam 25-30 min before endoscopy provided mild sedation.
    UNASSIGNED: IRCT201611039014N130 (05/11/2016); https://en.irct.ir/trial/9568.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号